Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194735 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase 1 study, sponsored by Alaunos Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05194735 is a Phase 1 study that was terminated before completion, run by Alaunos Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT05194735, a Phase 1 study, was terminated before completion, sponsored by Alaunos Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
Interventions
- BIOLOGICAL Aldesleukin (IL-2)
- BIOLOGICAL Neoantigen specific TCR-T cell drug product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2023-08-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05194735
The ClinicalTrials.gov registry entry for NCT05194735 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aldesleukin (IL-2) is the first listed.
NCT05194735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05194735 about?
NCT05194735 is a clinical study titled "Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors". A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
What is the current status of trial NCT05194735?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-04-04. Estimated completion is 2023-08-14.
What interventions are being tested in trial NCT05194735?
The interventions under investigation include: Aldesleukin (IL-2) (BIOLOGICAL), Neoantigen specific TCR-T cell drug product (BIOLOGICAL).
Who is sponsoring clinical trial NCT05194735?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.